STAT⁠44%

The biotech scorecard for the third quarter: 15 stock-moving events to watch ⁠41%

By Adam Feuerstein⁠43%

7/1/2026, 8:30:00 AM

BS Summary: This article contains 21 faulty reasoning types, including Appeal to Authority, Negativity Bias, and Optimism Bias, with Attempt to Sell a Product or Service as the most egregious example at 56.5% saturation with 157 hits. Analysis detected 688 faulty-reasoning hits from 278 analyzed words, generating a BS Score of 45.5% and a BS Rank of ⁠41% (13,028 of 21,886 articles). This article is better (less manipulative) than 59.50% of the article peer group.

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: 
Amylyx Pharmaceuticals: Results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia, a rare metabolic condition that causes severe drops in blood sugar. 
Biogen: In May, the company announced results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease called diranersen that targets the protein tau. 
Detailed data from the study will be presented on July 14 at the Alzheimer’s Association International Conference. 
This article is exclusive to STAT+ subscribers 
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. 
STAT+ Newsletter 
Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world 
Recommended 
STAT Plus: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong 
STAT Plus: A year after distressed buyout, what’s become of Bluebird Bio? 
Advertisement 
STAT Plus: Synthetic biology researchers think they’ve made a cell. 
Is it alive? 
STAT Plus: More signs that GLP-1s may help with peripheral artery disease 
STAT Plus: FDA approves Orca Bio’s T cell therapy for blood cancer patients 
Subscriber Picks 
STAT Plus: The ERs that can turn patients away — and are reaping millions 
STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry 
STAT Plus: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. 
Who was it? 
STAT Plus: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk 
STAT Plus: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes 
Article reasoning-pattern comparisonThis article: 5.4%Adam Feuerstein: 3.0%STAT: 3.4%Confirmation Bias5.4%This article: 0.0%Adam Feuerstein: 1.3%STAT: 1.3%Anchoring Bias0.0%This article: 8.6%Adam Feuerstein: 1.4%STAT: 3.9%Availability Heuristic8.6%This article: 5.8%Adam Feuerstein: 0.3%STAT: 1.0%Representativeness Heuristic5.8%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.4%Hindsight Bias0.0%This article: 0.0%Adam Feuerstein: 0.4%STAT: 1.3%Overconfidence Bias0.0%This article: 13.3%Adam Feuerstein: 11.1%STAT: 8.2%Framing Effect13.3%This article: 6.5%Adam Feuerstein: 1.3%STAT: 0.7%Loss Aversion6.5%This article: 0.0%Adam Feuerstein: 0.8%STAT: 0.9%Status Quo Bias0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.2%Sunk Cost Effect0.0%This article: 16.9%Adam Feuerstein: 8.5%STAT: 3.3%Optimism Bias16.9%This article: 0.0%Adam Feuerstein: 0.6%STAT: 1.8%Pessimism Bias0.0%This article: 20.9%Adam Feuerstein: 7.9%STAT: 8.5%Negativity Bias20.9%This article: 0.0%Adam Feuerstein: 1.1%STAT: 1.1%Self-Serving Bias0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.4%Fundamental Attribution Error0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Actor-Observer Bias0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.4%In-Group Bias0.0%This article: 5.8%Adam Feuerstein: 0.3%STAT: 0.1%Out-Group Homogeneity Bias5.8%This article: 13.7%Adam Feuerstein: 3.1%STAT: 1.3%Halo Effect13.7%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Horn Effect0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.0%Dunning-Kruger Effect0.0%This article: 4.3%Adam Feuerstein: 2.4%STAT: 1.6%Recency Bias4.3%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.4%Primacy Effect0.0%This article: 4.0%Adam Feuerstein: 0.2%STAT: 0.1%Blind-Spot Bias4.0%This article: 0.0%Adam Feuerstein: 0.2%STAT: 0.4%Ad Hominem0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.4%Straw Man0.0%This article: 25.5%Adam Feuerstein: 3.4%STAT: 4.7%Appeal to Authority25.5%This article: 1.1%Adam Feuerstein: 1.2%STAT: 1.5%False Dilemma1.1%This article: 0.0%Adam Feuerstein: 0.0%STAT: 1.2%Slippery Slope0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Circular Reasoning0.0%This article: 12.9%Adam Feuerstein: 1.8%STAT: 4.6%Hasty Generalization12.9%This article: 1.1%Adam Feuerstein: 1.0%STAT: 0.2%Red Herring1.1%This article: 0.0%Adam Feuerstein: 0.8%STAT: 0.4%Bandwagon0.0%This article: 16.2%Adam Feuerstein: 3.8%STAT: 3.6%Appeal to Emotion16.2%This article: 0.0%Adam Feuerstein: 1.4%STAT: 0.9%Begging the Question0.0%This article: 0.0%Adam Feuerstein: 1.0%STAT: 2.2%Post Hoc (False Cause)0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.0%Tu Quoque0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.7%Burden of Proof0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.2%Appeal to Nature0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.3%Composition/Division0.0%This article: 8.3%Adam Feuerstein: 1.3%STAT: 3.3%Anecdotal8.3%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%No True Scotsman0.0%This article: 11.2%Adam Feuerstein: 2.1%STAT: 2.1%Ambiguity (Equivocation)11.2%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.0%Gambler’s Fallacy0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.3%Middle Ground0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Personal Incredulity0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Special Pleading0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.1%Genetic Fallacy0.0%This article: 0.0%Adam Feuerstein: 0.7%STAT: 1.5%Unattributed Quote0.0%This article: 5.8%Adam Feuerstein: 0.7%STAT: 0.9%Quote-first Misdirection5.8%This article: 4.0%Adam Feuerstein: 4.4%STAT: 6.0%Biased Writer Voice4.0%This article: 0.0%Adam Feuerstein: 0.7%STAT: 2.1%Indoctrination0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.9%Politically Left Leaning Bias0.0%This article: 0.0%Adam Feuerstein: 0.0%STAT: 0.2%Politically Right Leaning Bias0.0%This article: 56.5%Adam Feuerstein: 15.2%STAT: 3.3%Attempt to Sell a Product or S…56.5%

278 words analyzed.

Speakers

5speakers74%attributed speech73writer words
Voice mapSelect a segment to jump to its words
Writer's voice • 12 words • 0.0% coverageWriter's voice • 16 words • 0.0% coverageAmylyx Pharmaceuticals • 25 words • 0.0% coverageBiogen • 25 words • 0.0% coverageWriter's voice • 17 words • 0.0% coverageSTAT+ • 7 words • 100.0% coverageWriter's voice • 18 words • 100.0% coverageSTAT+ • 2 words • 100.0% coverageAdam Feuerstein • 11 words • 100.0% coverageWriter's voice • 1 words • 0.0% coverageSTAT Plus • 16 words • 100.0% coverageSTAT Plus • 12 words • 100.0% coverageWriter's voice • 1 words • 0.0% coverageSTAT Plus • 10 words • 100.0% coverageWriter's voice • 3 words • 0.0% coverageSTAT Plus • 12 words • 100.0% coverageSTAT Plus • 13 words • 100.0% coverageWriter's voice • 2 words • 0.0% coverageSTAT Plus • 14 words • 100.0% coverageSTAT Plus • 14 words • 100.0% coverageSTAT Plus • 13 words • 100.0% coverageWriter's voice • 3 words • 0.0% coverageSTAT Plus • 15 words • 100.0% coverageSTAT Plus • 16 words • 100.0% coverage
Selected voice

STAT Plus

100%flagged-word coverage
135 attributed words66% of attributed speech95% writer coverage
0%45.0%90.0%Attempt to Sell a Product +63.5 ptsWriter: 24.7%STAT Plus: 88.1%88.1%Quote-first Misdirection+11.9 ptsWriter: 0.0%STAT Plus: 11.9%11.9%

Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.

Loading…
Loading…
Loading…
Loading…

Analysis

Hover over highlighted words in the article to view the associated bias or fallacy analysis.